Catalytic transfer hydrogenation and anticancer activity of arene-ruthenium compounds incorporating bi-dentate precursors.

Ruthenium based organometallic compounds are presently a subject of great attention as anticancer drugs and appear to work reasonably well on tumor cells. We develop a series of mononuclear arene-ruthenium compounds incorporating N,O and N,N bidentate ligands, and their activity as anticancer drugs against human hormone-refractory metastatic prostate cancer (HRMPCs) cell lines are investigated. The ruthenium compounds also act as effective catalysts in the transfer hydrogenation of the -C[double bond, length as m-dash]O- → -CH(OH)- system. Three types of ligands, namely, sodium glutamate, C4H3NH(2-CH2NH(t)Bu), and C4H3NH(2-CH[double bond, length as m-dash]NR) are separately coupled with [(η(6)-cymene)RuCl2]2 () (cymene = 4-isopropyltoluene) to synthesize five Ru-derivatives: [(η(6)-cymene)RuCl(κ(2)-N,O-OOCCHNH2CH2CH2COOH)] (), {(η(6)-cymene)RuCl[C4H3N(2-CH2NH(t)Bu)]} (), {(η(6)-cymene)RuCl[C4H3N(2-CH[double bond, length as m-dash]NCH2Ph)]} (), {(η(6)-cymene)RuCl{C4H3N[2-CH[double bond, length as m-dash]NCH2(C4H7O)]}} () and {(η(6)-cymene)RuCl[C4H3N(2-CH(n)BuNHCH2(C4H7O))]} (). To the best of our knowledge, the aforementioned Ru compounds are not only characterized by (1)H and (13)C NMR spectroscopy, but for the first time their structures have been established by single crystal X-ray diffractometry. Compound influences a concentration-dependent apoptosis in PC-3 cells and initiates the conversion rate in transfer hydrogenation.